자료실


Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen" by Tong et al.

After reading the article, see the complementary Gastroenterology article.

Abstract:
Background & Aims
During the natural course of chronic hepatitis B virus infection, a small proportion of patients experience hepatitis B surface antigen (HBsAg) seroclearance. However, the long-term clinical outcomes of this process are not well established.

Methods
Thirty-five patients with chronic hepatitis B, followed between 1976 and 2008 at a community liver clinic, experienced HBsAg seroclearance. Ten patients were Caucasian and 25 were Asian. These patients continued to undergo surveillance for hepatocellular carcinoma that included test for α-fetoprotein levels and abdominal ultrasound examinations. The median follow-up time was 185 months (range, 27–400 months).

Results
During the initial visit to the clinic, the median age of the patients was 41 years (range, 1.5–72 years). Eighteen patients (51.4%) were hepatitis B e antigen (HBeAg) positive 25 (71.4%) were hepatitis B virus DNA positive, and 13 (37.1%) had cirrhosis. At the time of HBsAg loss, the median age was 54 years (range, 13–77 years) and all were hepatitis B e antigen- as well as hepatitis B virus DNA negative. During the long-term follow-up, 4 patients with cirrhosis developed hepatocellular carcinoma (HCC), which was discovered by ultrasound examination. Factors associated with development of HCC were low baseline levels of albumin (P = .04), family histories of HBsAg positivity (P = .01) and HCC (P = .04), and age of less than 50 years at the time of HBsAg clearance (P = .03).

Conclusions
HCC can still develop after HBsAg seroclearance. Thus, surveillance should be continued after HBsAg loss in the same manner as for HBsAg positive patients.

Read the Article :  http://www.cghjournal.org/article/PIIS1542356509003723/abstract

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
(A) Patient A: a 55-year-old Asian male. (B) Patient B: a 67-year-old Asian male. (C) Patient C: a 69-year-old Caucasian male. (D) Patient D: a 73-year-old Asian male. AFP, alphafetoprotein; ALT, alanine aminotransferase.

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
번호 제목 글쓴이 날짜 조회 수
178 "간염보유자 취업차별은 부당합니다"(PPT 자료) [1] file 윤구현 2005.12.05 1761
177 비알콜성 지방간질환에서 당뇨병과 간기능(AST/ALT)의 의미 [1] 양전호 2009.11.10 1748
176 2009년 6월 1일. 페그인터페론(페가시스, 페그인트론) 보험급여 변경 [1] file 윤구현 2009.08.31 1744
175 대한의사협회 '급성A형간염 관련 회원 공지사항' [1] 윤구현 2009.07.23 1728
174 신약개발이야기1)나의 한 달 목숨값은 얼마인가? -프레시안 이은희 2003-02-13 [1] 윤구현 2003.04.11 1719
173 장해독, 간해독, 정화요법 [1] 한상율 2007.07.17 1698
172 간을 생각한다면 한약을 특히 조심하십시오 [3] 한상율 2007.07.04 1690
171 간질환에서 사용되어지는 약물 [1] file 양정채 2006.10.22 1681
170 신약개발이야기2) 신약개발, 그 멀고도 험난한 길 -프레시안 이은희 2003-02-19 [1] 윤구현 2003.04.11 1679
169 간암연구회 간암치료가이드라인 [3] file 양전호 2006.09.06 1675
168 심평원심사사례-YMDD mutant 발현시기 비교 헵세라 인정여부 2008.12.15. [1] 윤구현 2009.06.13 1670
167 (종료)B형간염수직감염예방을 위한 'HBIG(헤파빅)'용량조절사업안내문 [2] file 윤구현 2006.03.05 1665
166 2010년10월1일 B형간염치료제 보험급여 확대 [8] file 윤구현 2010.10.01 1664
165 만성간염환자들의 고민-우리를 슬프게 하는 것들. 2007년 간의날 발표문 [6] file 윤구현 2008.10.04 1662
164 제픽스, 헵세라 보험수가기준 행정해석 모음 [1] 윤구현 2005.12.14 1661
163 경구용 만성B형간염 치료제 급여 기준 2015-9-1 file 윤구현 2013.06.05 1649
162 2007년 대한간학회 만성B형간염치료 가이드라인 [2] file 윤구현 2008.01.11 1642
161 C형간염치료 [4] 양전호 2006.04.08 1640
160 서양에서 바라보는 간독성물질및 한약제 [1] 양전호 2006.03.29 1639
159 ’B형 간염바이러스 건강보유자 고용차별’ 해소를 위한 입법공청회 발제문 [4] file 윤구현 2005.04.15 1609